CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

GimsilumabWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)

Name (Synonyms) Correlation
drug108 Azithromycin Wiki 0.19
drug505 Hydroxychloroquine Wiki 0.11
drug850 Placebo Wiki 0.09

Correlated MeSH Terms (6)

Name (Synonyms) Correlation
D014947 Wounds and Injuries NIH 0.32
D055370 Lung Injury NIH 0.25
D013577 Syndrome NIH 0.13
D055371 Acute Lung Injury NIH 0.13
D012127 Respiratory Distress Syndrome, Newborn NIH 0.13
D012128 Respiratory Distress Syndrome, Adult NIH 0.11

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 A Multi-Center, Adaptive, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19.

Study KIN-1901-2001 is a multi-center, adaptive, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of gimsilumab in subjects with lung injury or acute respiratory distress syndrome (ARDS) secondary to COVID-19.

NCT04351243 Lung Injury or Acute Respiratory Distress Syndrome Due to COVID-19 Drug: Gimsilumab Drug: Placebo
MeSH:Respiratory Distress Syndrome, Newborn Respiratory Distress Syndrome, Adult Acute Lung Injury Lung Injury Syndrome Wounds and Injuries

Primary Outcomes

Description: Mortality at Day 43

Measure: Primary endpoint

Time: 43 days

Secondary Outcomes

Description: Subjects who die will be assigned "0" ventilator-free days

Measure: Number of ventilator-free days.

Time: Day 43

Measure: Number of days in the ICU

Time: Day 43

Measure: Number of days of inpatient hospitalization

Time: Day 43

Measure: Incidence of subjects who are alive and not on mechanical ventilation

Time: Days 15, 22, 29, and 43

No related HPO nodes (Using clinical trials)